Spectrum Pharmaceuticals: Key Drug Fusilev May Face Generic Competition Soon
- Fusilev's patent protection is much weaker than we or the market previously understood.
- We have counted at least five obvious prior arts, each of which is sufficient to invalidate the '829 patent.
- There is a high probability that generic competition for Fusilev could enter the market as early as March 2015.
- In that scenario, we believe the downside on SPPI's stock price would be extreme.